Ciltyri Approval Status
- FDA approved: No
- Brand name: Ciltyri
- Generic name: eplivanserin
- Company: Sanofi-Aventis U.S. LLC
- Treatment for: Insomnia
Ciltyri (eplivanserin) is a serotonin type 2 A receptor antagonist intended for use in patients with chronic insomnia characterized by difficulties with sleep maintenance.
In September 2009, Sanofi-Aventis announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Ciltyri (eplivanserin) had not been approved.
Development Status and FDA Approval Process for Ciltyri
|Sep 17, 2009||Sanofi-Aventis Receives Complete Response Letter from the FDA for eplivanserin (Ciltyri) Submission|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.